Douglas Miehm
Stock Analyst at RBC Capital
(3.75)
# 763
Out of 5,112 analysts
51
Total ratings
58.7%
Success rate
8.48%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $16.90 | +12.43% | 14 | Nov 14, 2025 | |
| MNKD MannKind | Maintains: Outperform | $8 → $7.5 | $5.97 | +25.63% | 4 | Nov 11, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $15.91 | -5.72% | 11 | Nov 5, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $6.82 | +46.63% | 21 | May 2, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $1.01 | +395.05% | 1 | Mar 10, 2025 |
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $16.90
Upside: +12.43%
MannKind
Nov 11, 2025
Maintains: Outperform
Price Target: $8 → $7.5
Current: $5.97
Upside: +25.63%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $15.91
Upside: -5.72%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $6.82
Upside: +46.63%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $1.01
Upside: +395.05%